WP
CMLTU

Woodline Partners’s CM Life Sciences III Inc. Unit CMLTU Stock Holding History

Woodline Partners’s Portfolio CMLTU Stock Details CMLTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,250,000
Closed -$13.7M – 786
2021
Q2 		$13.7M Buy
+1,250,000
New +$13.5M 0.26% 106

Other funds holding CMLTU

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
AMH
Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Woodline Partners's CMLTU Position: Q3 2021 in Review

Woodline Partners sold out of CM Life Sciences III Inc. Unit (CMLTU) in Q3 2021, closing a stake of 1,250,000 shares — an estimated $13.7M sold.

Woodline Partners first reported a position in CMLTU in Q2 2021 and held it in 1 quarter. The position peaked at $13.7M in Q2 2021. 28 funds tracked by Wall St. Rank hold CMLTU as of Q3 2021.

  • Woodline Partners reported no remaining CM Life Sciences III Inc. Unit position as of Q3 2021 after selling out during the quarter.
  • Woodline Partners sold 1,250,000 CM Life Sciences III Inc. Unit shares in Q3 2021, an estimated $13.7M.
  • Woodline Partners first reported a position in CM Life Sciences III Inc. Unit in Q2 2021 and held it in 1 quarter.
  • Woodline Partners's CM Life Sciences III Inc. Unit position peaked at $13.7M in Q2 2021.
  • 28 funds tracked by Wall St. Rank held CM Life Sciences III Inc. Unit as of Q3 2021.

Based on Woodline Partners's 13F filing for Q3 2021, filed 15 Nov 2021.